IPO for Prelude Therapeutics (PRLD) Paused on Volatility After Ramp Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Prelude Therapeutics (PRLD) IPO Opens 33% Higher
September 25, 2020 11:46 AM EDTToday's IPO for Prelude Therapeutics Incorporated (NASDAQ: PRLD) opened for trading at $25.23 after pricing its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.
In addition, Prelude Therapeutics has granted the underwriters a 30-day option... More
Prelude Therapeutics Inc. (PRLD) Prices 8.325M Share IPO at $19/Sh
September 25, 2020 6:17 AM EDTPrelude Therapeutics Incorporated (NASDAQ: PRLD) today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Prelude, before deducting underwriting commissions and offering expenses, are expected to be... More
